Its central bank Danias will significantly reduce its financial forecasts for 2025 due to the weaker increase in sales of Novo Nordisk and US dictatorialaccording to what her commander said.
In an interview on Thursday (4.9.2025), Christian Ketel Thomsen acknowledged that the prediction of his Foundation in March for growth slightly higher than last year’s 3.5% is no longer realistic, given the combined discomfort of the Danish pharmaceutical giant. 15% duty imposed by US President Donald Trump In the products of the European Union.
“Certainly We will reduce our growth predictions“, Said the commander of Novo Nordisk. “We will probably reduce them significantly, as we have seen from other analysts.”
Thomsen’s observations indicate the benefits and dangers of US demand for prosperity, as both the challenges of NOVO and Trump’s duties have appeared there in recent months. The Danish economy, for which Brussels officials predicted just in May that it would make the most growth in the EU this year after Malta, may now end up having a moderate performance in the block.
The Commander warned that even a significantly lower growth rate would not change the image in the interior of the country, and it was also implied that The result may not be as bad as the 1.4% predicted last week by the Ministry of Economy. “It is not a completely different development image, as the numbers may indicate if we pass from 3.6% to about 2% or something,” Thomsen said. “It’s not as dramatic as that.”
Novo’s successful medicines For obesity and diabetes, Wegovy και Ozempicthey have turned it into the most important Denmark company, with a production scale that can change national accounts.
The pharmaceutical company has twice reduced its forecasts for sales and profits of 2025 this year, due to increasing competition and increasing imitation of its products in the US. Its shares have fallen by almost two -thirds from last year’s high level, negatively affecting the climate of consumer confidence in the domestic market.
“We are watching them closely,” Thomsen said. “We are very interested in the evolution of the situation. For the last three to four years, Novo’s importance to the Danish economy has increased. ”
The decline in pharmaceutical production has already triggered the economy in the first quarter, further deteriorating the provisions, the commander said. He added that US duties may reduce GDP by about 0.5%. The Central Bank is expected to publish revised forecasts on September 24.
Thomsen said that Novo’s oversized role is something that is of interest to his counterparts in the Central Bank, who are wondering how vulnerable the Danish economy is in its performance.
However, the commander insisted that the company’s problems are not particularly concerned, mainly because Its sales continue to grow and Denmark has historically withstanding the downside to large companies. Most of Novo’s production is outside the country, which should mitigate the impact on the labor market and local wealth, Thomsen said.
“We do not think we are under serious threat, but it is important not to rest,” he said.
Novo employs more than 30,000 people in Denmark, just over 1% of the economy’s workforce. Without the contribution of the pharmaceutical industry, growth would have been reduced by half in 2024 and would have been negative in the previous two years, according to the National Statistical Service.